-
1
-
-
0027405070
-
Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region
-
Ali S, Metzger D, Bornert JM, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 1993;12:1153-60.
-
(1993)
EMBO J.
, vol.12
, pp. 1153-1160
-
-
Ali, S.1
Metzger, D.2
Bornert, J.M.3
Chambon, P.4
-
2
-
-
0027978187
-
Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor
-
Arnold SF, Obourn JD, Jaffe H, Notides AC. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 1994;8:1208-14.
-
(1994)
Mol. Endocrinol.
, vol.8
, pp. 1208-1214
-
-
Arnold, S.F.1
Obourn, J.D.2
Jaffe, H.3
Notides, A.C.4
-
3
-
-
0028111526
-
Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity
-
Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994;269:4458-66.
-
(1994)
J. Biol. Chem.
, vol.269
, pp. 4458-4466
-
-
Le Goff, P.1
Montano, M.M.2
Schodin, D.J.3
Katzenellenbogen, B.S.4
-
4
-
-
0028886694
-
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
-
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
-
(1995)
Science
, vol.270
, pp. 1491-1494
-
-
Kato, S.1
Endoh, H.2
Masuhiro, Y.3
Kitamoto, T.4
Uchiyama, S.5
Sasaki, H.6
-
5
-
-
0029877913
-
Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
-
Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
-
(1996)
EMBO J.
, vol.15
, pp. 2174-2183
-
-
Bunone, G.1
Briand, P.A.2
Miksicek, R.J.3
Picard, D.4
-
6
-
-
0028997307
-
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
-
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
-
(1995)
Oncogene
, vol.10
, pp. 2435-2446
-
-
Pietras, R.J.1
Arboleda, J.2
Reese, D.M.3
Wongvipat, N.4
Pegram, M.D.5
Ramos, L.6
-
7
-
-
0033305547
-
Nuclear receptor coregulators: Cellular and molecular biology
-
McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
-
(1999)
Endocr. Rev.
, vol.20
, pp. 321-344
-
-
McKenna, N.J.1
Lanz, R.B.2
O'Malley, B.W.3
-
8
-
-
0030998328
-
The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
-
Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997;11:693-705.
-
(1997)
Mol. Endocrinol.
, vol.11
, pp. 693-705
-
-
Jackson, T.A.1
Richer, J.K.2
Bain, D.L.3
Takimoto, G.S.4
Tung, L.5
Horwitz, K.B.6
-
10
-
-
11744282298
-
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
-
Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998;95:2920-5.
-
(1998)
Proc. Natl. Acad. Sci. U S A
, vol.95
, pp. 2920-2925
-
-
Lavinsky, R.M.1
Jepsen, K.2
Heinzel, T.3
Torchia, J.4
Mullen, T.M.5
Schiff, R.6
-
11
-
-
0032446607
-
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
-
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
-
(1998)
Cell
, vol.95
, pp. 927-937
-
-
Shiau, A.K.1
Barstad, D.2
Loria, P.M.3
Cheng, L.4
Kushner, P.J.5
Agard, D.A.6
-
12
-
-
0030946198
-
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
-
Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66.
-
(1997)
Mol. Endocrinol.
, vol.11
, pp. 657-666
-
-
Smith, C.L.1
Nawaz, Z.2
O'Malley, B.W.3
-
13
-
-
0030797902
-
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
-
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
-
(1997)
Science
, vol.277
, pp. 965-968
-
-
Anzick, S.L.1
Kononen, J.2
Walker, R.L.3
Azorsa, D.O.4
Tanner, M.M.5
Guan, X.Y.6
-
14
-
-
0030912539
-
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
-
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997;387:677-84.
-
(1997)
Nature
, vol.387
, pp. 677-684
-
-
Torchia, J.1
Rose, D.W.2
Inostroza, J.3
Kamei, Y.4
Westin, S.5
Glass, C.K.6
-
15
-
-
0030872716
-
RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
-
Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A 1997;94:8479-84.
-
(1997)
Proc. Natl. Acad. Sci. U S A
, vol.94
, pp. 8479-8484
-
-
Li, H.1
Gomes, P.J.2
Chen, J.D.3
-
16
-
-
0030740253
-
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
-
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997;90:569-80.
-
(1997)
Cell
, vol.90
, pp. 569-580
-
-
Chen, H.1
Lin, R.J.2
Schiltz, R.L.3
Chakravarti, D.4
Nash, A.5
Nagy, L.6
-
17
-
-
0033707074
-
Altered expression of estrogen receptor coregulators during human breast tumorigenesis
-
Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 2000;60:6266-71.
-
(2000)
Cancer Res.
, vol.60
, pp. 6266-6271
-
-
Murphy, L.C.1
Simon, S.L.2
Parkes, A.3
Leygue, E.4
Dotzlaw, H.5
Snell, L.6
-
18
-
-
0032406875
-
In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity
-
Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998;4:2925-9.
-
(1998)
Clin. Cancer Res.
, vol.4
, pp. 2925-2929
-
-
Bautista, S.1
Valles, H.2
Walker, R.L.3
Anzick, S.4
Zeillinger, R.5
Meltzer, P.6
-
19
-
-
0035110716
-
Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu
-
Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001;61:903-7.
-
(2001)
Cancer Res.
, vol.61
, pp. 903-907
-
-
Bouras, T.1
Southey, M.C.2
Venter, D.J.3
-
20
-
-
0035968330
-
Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells
-
List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 2001;276:23763-8.
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 23763-23768
-
-
List, H.J.1
Lauritsen, K.J.2
Reiter, R.3
Powers, C.4
Wellstein, A.5
Riegel, A.T.6
-
21
-
-
0001392322
-
AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
-
Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
-
(2000)
Mol. Cell Biol.
, vol.20
, pp. 5041-5047
-
-
Font de Mora, J.1
Brown, M.2
-
22
-
-
0027074588
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
-
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
-
(1993)
Breast Cancer Res. Treat.
, vol.24
, pp. 85-95
-
-
Benz, C.C.1
Scott, G.K.2
Sarup, J.C.3
Johnson, R.M.4
Tripathy, D.5
Coronado, E.6
-
23
-
-
0034473776
-
The role of HER-2 expression in predicting response to therapy in breast cancer
-
discussion 92-100
-
Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27:46-52; discussion 92-100.
-
(2000)
Semin. Oncol.
, vol.27
, pp. 46-52
-
-
Mass, R.1
-
24
-
-
0033834513
-
Molecular markers for predicting response to tamoxifen in breast cancer patients
-
Ciocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;13:1-10.
-
(2000)
Endocrine
, vol.13
, pp. 1-10
-
-
Ciocca, D.R.1
Elledge, R.2
-
25
-
-
0033050838
-
Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
-
Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999;69:45-50.
-
(1999)
J. Steroid Biochem. Mol. Biol.
, vol.69
, pp. 45-50
-
-
Takimoto, G.S.1
Graham, J.D.2
Jackson, T.A.3
Tung, L.4
Powell, R.L.5
Horwitz, L.D.6
-
26
-
-
0036242554
-
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase
-
Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase. Mol Cell Biol 2002;22:3549-61.
-
(2002)
Mol. Cell Biol.
, vol.22
, pp. 3549-3561
-
-
Wu, R.C.1
Qin, J.2
Hashimoto, Y.3
Wong, J.4
Xu, J.5
Tsai, S.Y.6
-
27
-
-
0032896905
-
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
-
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1474-1481
-
-
Harvey, J.M.1
Clark, G.M.2
Osborne, C.K.3
Allred, D.C.4
-
28
-
-
0032443239
-
S-phase fraction and breast cancer - A decade of experience
-
Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1998;51:255-65.
-
(1998)
Breast Cancer Res. Treat.
, vol.51
, pp. 255-265
-
-
Wenger, C.R.1
Clark, G.M.2
-
29
-
-
0030951877
-
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
-
Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997;15:1916-22.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1916-1922
-
-
Elledge, R.M.1
Green, S.2
Howes, L.3
Clark, G.M.4
Berardo, M.5
Allred, D.C.6
-
30
-
-
0024360141
-
HER-2/neu oncogene protein and prognosis in breast cancer
-
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
-
(1989)
J. Clin. Oncol.
, vol.7
, pp. 1120-1128
-
-
Tandon, A.K.1
Clark, G.M.2
Chamness, G.C.3
Ullrich, A.4
McGuire, W.L.5
-
31
-
-
33845382806
-
Non-parametric estimation for incomplete observation
-
Kaplan E, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-71.
-
(1958)
J. Am. Stat. Assoc.
, vol.53
, pp. 457-471
-
-
Kaplan, E.1
Meier, P.2
-
32
-
-
0000957062
-
Asymptotically efficient rank invariant test procedures
-
(with discussion)
-
Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 1972;135:185-207.
-
(1972)
J. R. Stat. Soc. A
, vol.135
, pp. 185-207
-
-
Peto, R.1
Peto, J.2
-
33
-
-
0000336139
-
Regression models and life table
-
(with discussion)
-
Cox D. Regression models and life table (with discussion). J R Stat Soc B 1972;34:187-202.
-
(1972)
J. R. Stat. Soc. B
, vol.34
, pp. 187-202
-
-
Cox, D.1
-
34
-
-
70449647008
-
Proportional hazards tests and diagnostics based on weighted residuals
-
Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
-
(1994)
Biometrika
, vol.81
, pp. 515-526
-
-
Grambsch, P.1
Therneau, T.2
-
35
-
-
0035878970
-
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history
-
Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001;61:5420-4.
-
(2001)
Cancer Res.
, vol.61
, pp. 5420-5424
-
-
Rebbeck, T.R.1
Wang, Y.2
Kantoff, P.W.3
Krithivas, K.4
Neuhausen, S.L.5
Godwin, A.K.6
-
36
-
-
0024322655
-
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
-
Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-8.
-
(1989)
Am. J. Epidemiol.
, vol.130
, pp. 221-228
-
-
Bergkvist, L.1
Adami, H.O.2
Persson, I.3
Bergstrom, R.4
Krusemo, U.B.5
-
37
-
-
0032989896
-
Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients
-
Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999;80:1453-8.
-
(1999)
Br. J. Cancer
, vol.80
, pp. 1453-1458
-
-
Jernstrom, H.1
Frenander, J.2
Ferno, M.3
Olsson, H.4
-
38
-
-
0344517349
-
Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
-
Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999;281:2091-7.
-
(1999)
JAMA
, vol.281
, pp. 2091-2097
-
-
Gapstur, S.M.1
Morrow, M.2
Sellers, T.A.3
-
39
-
-
0034814296
-
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue
-
List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001;68:21-8.
-
(2001)
Breast Cancer Res. Treat.
, vol.68
, pp. 21-28
-
-
List, H.J.1
Reiter, R.2
Singh, B.3
Wellstein, A.4
Riegel, A.T.5
-
41
-
-
0037192501
-
Molecular determinants for the tissue specificity of SERMs
-
Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
-
(2002)
Science
, vol.295
, pp. 2465-2468
-
-
Shang, Y.1
Brown, M.2
-
42
-
-
0035747593
-
Interpreting and integrating risk factors for patients with primary breast cancer
-
Clark GM. Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001;30:17-21.
-
(2001)
J. Natl. Cancer Inst. Monogr.
, vol.30
, pp. 17-21
-
-
Clark, G.M.1
-
43
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
-
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Mauriac, L.4
Llombert-Cussac, A.5
Janicke, F.6
|